Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5a.
Fig. 5b.
Fig. 5c.
Fig. 6.
Pharmacokinetic parameters of enrofloxacin in year-old Cornu aspersum maxima snails after single intrahaemolymphatic (IHL) (1 mg/kg), gavage and medicated wafer (30 mg/kg) administrations (n = 3 × 65)
| Parameter | IHL | By cannula | By wafer |
|---|---|---|---|
| R2 | 0.918 | 0.9585 | 1 |
| λz(1/h) | 0.0354 | 0.0463 | 0.0366 |
| HL λz (h) | 19.5677 | 14.9812 | 18.9184 |
| Tmax (h) | / | 0.75 | 4 |
| Cmax (ng/mL) | / | 19,064 | 12,745 |
| AUClast/D (h*ng/mL) | 20,838 | 5,963 | 15,130 |
| AUCinf/D (h*/ng/mL) | 22,250 | 6,161 | 16,495 |
| Vz (mL/kg) | 1,268.755 | / | / |
| Cl (mL*h/kg) | 44.9432 | / | / |
| MRT (h) | 19.2014 | 15.493 | 30.0288 |
Validation results of the quantification analysis of enrofloxacin and ciprofloxacin in haemolymph, mucus, albumen gland, muscle and hepatopancreas of year-old Cornu aspersum maxima snails
| Parameter | Enrofloxacin | Ciprofloxacin | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Matrix | ||||||||||
| Haemolymph | Mucus | Albumen gland | Muscle | Hepatopancreas | Haemolymph | Mucus | Albumen gland | Muscle | Hepatopancreas | |
| R2 | 0.991 | 0.992 | 0.994 | 0.995 | 0.993 | 0.992 | 0.993 | 0.991 | 0.993 | 0.993 |
| Repeatability, CV,% | 8.6 | 7.5 | 7.4 | 6.9 | 6.6 | 7.0 | 6.8 | 9.1 | 7.3 | 5.9 |
| Reproducibility, CV, % | 10.4 | 8.3 | 8.7 | 8.1 | 7.8 | 8.2 | 7.9 | 11.5 | 9.1 | 8.8 |
| Recovery,% | 96.6 | 102.8 | 97.5 | 96.1 | 101 | 94.9 | 105.6 | 99.1 | 95.8 | 99.5 |
| LOQ (μg/L) | 5 | - | - | - | - | 10 | - | - | - | - |
| LOQ (μg/kg) | - | 5 | 5 | 5 | 5 | - | 10 | 10 | 10 | 10 |